SynAct Pharma: Another Directed Share Issue Solves Funding
4 juni, 11:48
4 juni, 11:48
Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of which have attractive conditions for the company. This funding will enable SynAct to start a new phase IIa study in polymyalgia rheumatica, which will have a positive impact on our base case.
4 juni, 11:48
Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of which have attractive conditions for the company. This funding will enable SynAct to start a new phase IIa study in polymyalgia rheumatica, which will have a positive impact on our base case.
Investmentbolagen
Aktieråd
VD-sortin i Rusta
Investmentbolagen
Aktieråd
VD-sortin i Rusta
1 DAG %
Senast
Idag, 08:44
Kivra ska lansera BankID-utmanare
Idag, 07:44
Modehandeln föll rejält i maj
Fortnox
Idag, 07:41
Budgivarna fullföljer Fortnox-budet
OMX Stockholm 30
1 DAG %
Senast
2 469,73